Study in EpCAM Positive Patients With Symptomatic Malignant Ascites Using Removab Versus an Untreated Control Group
The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.
EpCam Positive Tumor (e.g.Ovarian, Gastric, Colon, Breast)|Malignant Ascites
BIOLOGICAL: Catumaxomab (Removab)|PROCEDURE: paracentesis
The study will be performed to obtain further efficacy and safety data in order to obtain a marketing authorization (pivotal study). In addition, health economic data are to be collected.